Can a simple ultrasound predict immunotherapy success?

NCT ID NCT05206942

Terminated Diagnosis Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ultrasound can predict which patients will respond, potentially offering a faster, safer alternative to waiting for standard scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Doppler ultrasound, Long Ensemble Angular-coherence Doppler ultrasound, Contrast-enhanced ultrasound (CEUS) with Lumason contrast agent
What this could lead to: If successful, this could lead to a non-invasive way to quickly tell if immunotherapy is working, helping doctors adjust treatment sooner.
What could go wrong: This is a small, early-stage study (30 participants) that is currently suspended. The ultrasound methods may not reliably predict response, and results may not apply to all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Stanford

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.